PMS in the perimenopause

Journal of the British Menopause Society

Volumn 10, Issue 4, 2004, Pages 151-156

  Hassan, Ismail M ^a   Ismail, Khaled M K ^a   O'Brien, Shaughn ^a  

^a UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

Neurotransmitters; Oestrogen; Perimenopause; Premenstrual dysphoric disorder; Premenstrual syndrome; Progesterone

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANDROGEN; ANDROSTENEDIONE; DANAZOL; DOPAMINE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; GONADORELIN AGONIST; NORADRENALIN; PROGESTERONE; PYRIDOXINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE BINDING GLOBULIN; TIBOLONE;

CLIMACTERIUM; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MENSTRUAL CYCLE; NEUROTRANSMISSION; OVULATION; PATHOPHYSIOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

DECISION TREES; FEMALE; HUMANS; PERIMENOPAUSE; PREMENSTRUAL SYNDROME;

EID: 11244318214     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/1362180042721111     Document Type: Review

References (65)

1. Cohen LS, Soares CN, Otto MW et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70: 125-132.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington DC 1994.
3. World Health Organization. Mental, behavioral and developmental disorders. 1996.
4. Dennerstein L, Randolph J, Taffe J et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002; 77 (Suppl 4): S42-S48.
5. Schmidt PJ, Roca CA, and Rubinow DR. Clinical evaluation in studies of perimenopausal women: position paper. Psychopharmacol Bull 1998; 34: 309-311.
6. Freeman MP, Smith KW, Freeman SA et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002; 63: 284-287.
7. Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003; 289: 895-902.
8. Metcalf MG. Incidence of ovulation from the menarche to the menopause: observations of 622 New Zealand women. N Z Med J 1983; 96: 645-648.
9. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001; 15: 797-817.
10. Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging 2003; 20: 85-100.
11. Khastgir G, Studd J. Hysterectomy, ovarian failure, and depression. Menopause 1998; 5: 113-122.
12. Halbreich U. Role of estrogen in postmenopausal depression. Neurology 1997; 48: S16-S19.
13. Schmidt PJ, Nieman L, Danaceau MA et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183: 414-420.
14. Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 mcg and 200 mcg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475-484.
15. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58: 529-534.
16. Meltzer HY. Role of serotonin in depression. Ann N Y Acad Sci 1990; 600: 486-499.
17. Liu P, He IF, Bai WP, et al. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J (Engl ) 2004; 117: 189-194.
18. Westlund TL, Parry BL. Does estrogen enhance the antide-pressant effects of fluoxetine? J Affect Disord 2003; 77: 87-92.
19. Gruber CJ, Huber JC. Differential effects of progestins on the brain. Maturitas 2003; 46 (Suppl 1): S71-S75.
20. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6: 2311-2322.
21. Purdy RH, Morrow AL, Moore PH Jr, et al. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci 1991; 88: 4553-4557.
22. Gandolfo G, Scherschlicht R, Gottesmann C. Benzodiazepines promote the intermediate stage at the expense of paradoxical sleep in the rat. Pharmacol Biochem Behav 1994; 49: 921-927.
23. Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav 1993; 45: 423-428.
24. Korneyev A, Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Horm Behav 1996; 30: 37-43.
25. Picazo O, Fernandez-Guasti A. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res 1995; 680: 135-141.
26. Genazzani AR, Gambacciani M, Simoncini T, et al. Controversial issues in climacteric medicine series, 3rd Pisa workshop. Maturitas 2003; 46: 7-26.
27. Burger HG, Dudley EC, Cui J, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000; 85: 2832-2838.
28. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, et al. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 645-651.
29. Overlie I, Moen MH, Morkrid L et al. The endocrine transition around menopause-a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand 1999; 78: 642-647.
30. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-665.
31. Davis SR, Burger HG. The role of androgen therapy. Best Pract Res Clin Endocrinol Metab 2003; 17: 165-175.
32. Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992; 6: 57-64.
33. Bjorn I, Bixo M, Nojd KS, et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002; 16: 1-8.
34. Henshaw C, Foreman D, et al. Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy? J Psychosom Obstet Gynaecol 1996; 17: 21-28.
35. Wyatt K, Dimmock P, Jones P et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323: 776-780.
36. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder. Am J Obstet Gynecol 1988; 158: 5-11.
37. Elliott H. Premenstrual dysphoric disorder. A guide for the treating clinician. N C Med J 2002; 63: 72-75.
38. Rapkin AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol 1992; 35: 629-636.
39. Biegon A, Bercovitz H, Samuel D. Serotonin receptor concentration during the estrous cycle of the rat. Brain Res 1980; 187: 221-225.
40. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356: 1131-1136.
41. Halbreich U, Petty F, Yonkers K, et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153: 718-720.
42. Lloyd KG, Zivkovic B, Scatton B, et al. The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 341-351.
43. Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 2000; 14: 23-45.
44. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 1998; 44: 865-873.
45. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709-714.
46. Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am 2000; 27: 625-639.
47. Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993; 29: 193-200.
48. Hartlage SA, Gehlert S. Differentiating premenstrual dysphoric disorder from premenstrual exacerbations of other disorders: a methods dilemma. Clinical Psychology: Science and Practice 2001; 8: 242-253.
49. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003; 6: 203-209.
50. Frackiewicz EJ, Cutler NR. Women's health care during the perimenopause. J Am Pharm Assoc (Wash ) 2000; 40: 800-811.
51. Pop VJ, Maartens LH, Leusink G et al. Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998; 83: 3194-3197.
52. Ladenson PW, Singer PA, Ain KB et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573-1575.
53. MeReC Publication. Tackling premenstrual syndrome. MeReC Bulletin 2002; 13: 9-12.
54. Born L, Steiner M. Current management of premenstrual syndrome and premenstrual dysphoric disorder. Curr Psychiatry Rep 2001; 3: 463-469.
55. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999; 14 (Suppl 2): S27-S33.
56. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; CD001396.
57. Epperson CN, Wisner KL. Gonadal steroids in the treatment of mood disorders. Psychosom Med 1999; 61: 676-97.
58. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33: 303-309.
59. Brown CS, Ling FW, Andersen RN et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779-786.
60. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105-109.
61. Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 99-105.
62. Johnson SR. Premenstrual syndrome therapy. Clin Obstet Gynecol 1998; 41: 405-421.
63. Mezrow G, Shoupe D, Spicer D et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932-937.
64. Di Carlo C, Palomba S, Tommaselli GA et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75: 380-384.
65. Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 2: 730-732.